Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis

Table 1 Demographical and clinical characteristics of the two groups

	PSC-IBD (n = 75)		IBD without PSC (n = 150)		P
Male (%)	53.3		53.3		1
Age at IBD diagnosis (yr) (mean + SD)	27.8 (14)		28.5 (14)		0.75
Age at PSC diagnosis (yr) (mean + SD)	35.8 (15.6)		NA
IBD Follow up (mo) (mean + SD)	172 (133)		132 (123)		0.025
Initial/Cumulative IBD location (%)
Pancolitis	41 (55.4)	49 (66.2)	74 (49.3)	91 (60.7)	0.39	0.65
Rectal sparing	18 (24.3)	15 (20.3)	30 (20)	20 (13.3)	0.46	0.18
Sigmoid colon involvement	64 (86.5)	68 (91.9)	132 (88.6)	138 (92.6)	0.65	0.85
Left colon involvement	60 (81.1)	68 (91.9)	113 (75.8)	130 (87.2)	0.38	0.3
Right colon involvement	55 (74.3)	61 (82.4)	93 (62.4)	109 (72.7)	0.076	0.13
Ileum involvement	9 (12)	14 (18.7)	19 (12.7)	36 (24)	0.88	0.36
Jejunum involvement	0	1 (1.3)	0	3 (2)	1	0.59
Upper gastrointestinal tract involvement	1 (1.3)	1 (1.3)	4 (2.7)	8 (5.3)	0.46	0.14
Extra-intestinal manifestations (%)
Articular	16 (21.3)		34 (22.7)		0.82
Oral aphtae	3 (4)		4 (2.7)		0.58
Skin	8 (10.7)		7 (4.7)		0.09
Muscular	0		1 (0.7)		0.67
Ophthalmological	0		4 (2.7)		0.19
At least one extra intestinal lesion	22 (29.3)		39 (26)		0.59
Initial/Final diagnosis (%)
CD	19 (25.3)	21 (28)	43 (28.7)	62 (41.3)	0.6	0.051
UC	40 (53.3)	42 (56)	94 (62.7)	80 (53.3)	0.18	0.7
IC	1 (1.3)	1 (1.3)	1 (0.7)	3 (2)	0.61	0.72
IBDu	15 (20)	11 (14.7)	12 (8)	5 (3.3)	0.009	0.002
Smoking At IBD diagnosis/After IBD diagnosis	4 (5.3)	6 (8)	45 (30)	49 (32.7)	< 0.001	< 0.001
Colorectal neoplasia (%)
Dysplasia	2 (2.7)		1 (0.7)		0.2
Carcinoma	8 (10.7)		1 (0.7)		< 0.001
Appendectomy (%)	9 (12.7)		30 (20.3)		0.25

PSC-IBD: Inflammatory bowel disease associated with primary sclerosing cholangitis; CD: Crohn’s disease; UC: Ulcerative colitis; IC: Indeterminate colitis; IBDu: Unclassified IBD; NA: Not applicable.